Which has preferable earnings & valuation, BVS or WRBY?

Bioventus has higher earnings, but lower revenue than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $576.30M 1.52 $22.73M $0.41 25.56 Warby Parker $871.91M 3.58 $1.64M $0.02 1,458.75

Is BVS or WRBY more profitable?

Bioventus has a net margin of 4.94% compared to Warby Parker's net margin of 0.15%. Bioventus' return on equity of 29.97% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Warby Parker 0.15% 2.30% 1.18%

Does the media refer more to BVS or WRBY?

In the previous week, Warby Parker had 11 more articles in the media than Bioventus. MarketBeat recorded 13 mentions for Warby Parker and 2 mentions for Bioventus. Warby Parker's average media sentiment score of 0.72 beat Bioventus' score of 0.33 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Warby Parker 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BVS or TMDX?

TransMedics Group has higher revenue and earnings than Bioventus. TransMedics Group is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $576.30M 1.52 $22.73M $0.41 25.56 TransMedics Group $605.49M 3.93 $190.29M $4.40 15.65

Does the media refer more to BVS or TMDX?

In the previous week, TransMedics Group had 4 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for TransMedics Group and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.33 beat TransMedics Group's score of 0.15 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ESTA or BVS?

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 12.44 -$51.06M -$1.49 N/A Bioventus $576.30M 1.52 $22.73M $0.41 25.56

Does the media favor ESTA or BVS?

In the previous week, Establishment Labs and Establishment Labs both had 2 articles in the media. Establishment Labs' average media sentiment score of 1.21 beat Bioventus' score of 0.33 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, AXGN or BVS?

Bioventus has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 10.25 -$15.70M -$0.64 N/A Bioventus $576.30M 1.52 $22.73M $0.41 25.56

Is AXGN or BVS more profitable?

Bioventus has a net margin of 4.94% compared to AxoGen's net margin of -13.21%. Bioventus' return on equity of 29.97% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% Bioventus 4.94% 29.97% 9.52%

Does the media refer more to AXGN or BVS?

In the previous week, AxoGen had 2 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for AxoGen and 2 mentions for Bioventus. AxoGen's average media sentiment score of 1.39 beat Bioventus' score of 0.33 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BVS or LMAT?

In the previous week, LeMaitre Vascular had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for LeMaitre Vascular and 2 mentions for Bioventus. LeMaitre Vascular's average media sentiment score of 1.41 beat Bioventus' score of 0.33 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LeMaitre Vascular 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bioventus (BVS) Competitors

$10.48 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$10.68 +0.20 (+1.86%)

As of 07/2/2026 07:56 PM Eastern

Compare

BVS vs. WRBY, TMDX, ESTA, AXGN, and LMAT

Should you buy Bioventus stock or one of its competitors? MarketBeat compares Bioventus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventus include Warby Parker (WRBY), TransMedics Group (TMDX), Establishment Labs (ESTA), AxoGen (AXGN), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

How does Bioventus compare to Warby Parker?

Bioventus (NASDAQ:BVS) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Bioventus has higher earnings, but lower revenue than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56
Warby Parker	$871.91M	3.58	$1.64M	$0.02	1,458.75

Bioventus currently has a consensus price target of $14.20, indicating a potential upside of 35.50%. Warby Parker has a consensus price target of $29.82, indicating a potential upside of 2.20%. Given Bioventus' stronger consensus rating and higher possible upside, equities analysts plainly believe Bioventus is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Warby Parker has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Bioventus has a net margin of 4.94% compared to Warby Parker's net margin of 0.15%. Bioventus' return on equity of 29.97% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Warby Parker	0.15%	2.30%	1.18%

62.9% of Bioventus shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Warby Parker had 11 more articles in the media than Bioventus. MarketBeat recorded 13 mentions for Warby Parker and 2 mentions for Bioventus. Warby Parker's average media sentiment score of 0.72 beat Bioventus' score of 0.33 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bioventus beats Warby Parker on 9 of the 17 factors compared between the two stocks.

How does Bioventus compare to TransMedics Group?

Bioventus (NASDAQ:BVS) and TransMedics Group (NASDAQ:TMDX) are both medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

TransMedics Group has a net margin of 27.04% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
TransMedics Group	27.04%	22.38%	8.46%

TransMedics Group has higher revenue and earnings than Bioventus. TransMedics Group is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56
TransMedics Group	$605.49M	3.93	$190.29M	$4.40	15.65

In the previous week, TransMedics Group had 4 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for TransMedics Group and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.33 beat TransMedics Group's score of 0.15 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

Bioventus presently has a consensus price target of $14.20, indicating a potential upside of 35.50%. TransMedics Group has a consensus price target of $134.50, indicating a potential upside of 95.32%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats Bioventus on 10 of the 17 factors compared between the two stocks.

How does Bioventus compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Establishment Labs presently has a consensus target price of $87.14, indicating a potential downside of 2.36%. Bioventus has a consensus target price of $14.20, indicating a potential upside of 35.50%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.44	-$51.06M	-$1.49	N/A
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56

In the previous week, Establishment Labs and Establishment Labs both had 2 articles in the media. Establishment Labs' average media sentiment score of 1.21 beat Bioventus' score of 0.33 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Establishment Labs has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Bioventus has a net margin of 4.94% compared to Establishment Labs' net margin of -19.05%. Bioventus' return on equity of 29.97% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Bioventus	4.94%	29.97%	9.52%

Summary

Bioventus beats Establishment Labs on 11 of the 16 factors compared between the two stocks.

How does Bioventus compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 1.33%. Bioventus has a consensus price target of $14.20, suggesting a potential upside of 35.50%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	10.25	-$15.70M	-$0.64	N/A
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56

Bioventus has a net margin of 4.94% compared to AxoGen's net margin of -13.21%. Bioventus' return on equity of 29.97% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Bioventus	4.94%	29.97%	9.52%

AxoGen has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, AxoGen had 2 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for AxoGen and 2 mentions for Bioventus. AxoGen's average media sentiment score of 1.39 beat Bioventus' score of 0.33 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bioventus beats AxoGen on 11 of the 17 factors compared between the two stocks.

How does Bioventus compare to LeMaitre Vascular?

Bioventus (NASDAQ:BVS) and LeMaitre Vascular (NASDAQ:LMAT) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

LeMaitre Vascular has a net margin of 24.35% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
LeMaitre Vascular	24.35%	15.36%	9.78%

LeMaitre Vascular has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56
LeMaitre Vascular	$249.60M	9.42	$57.73M	$2.71	37.96

62.9% of Bioventus shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, LeMaitre Vascular had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for LeMaitre Vascular and 2 mentions for Bioventus. LeMaitre Vascular's average media sentiment score of 1.41 beat Bioventus' score of 0.33 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus currently has a consensus price target of $14.20, suggesting a potential upside of 35.50%. LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 9.45%. Given Bioventus' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bioventus is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

LeMaitre Vascular beats Bioventus on 9 of the 15 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$875.45M	$3.23B	$5.21B	$12.47B
Dividend Yield	N/A	N/A	16.10%	6.50%
P/E Ratio	25.56	20.07	23.91	24.70
Price / Sales	1.52	334.15	168.34	97.92
Price / Cash	8.22	9.27	35.06	57.09
Price / Book	3.80	5.79	13.25	6.46
Net Income	$22.73M	$7.39M	$113.80M	$337.01M
7 Day Performance	7.16%	0.70%	0.93%	1.69%
1 Month Performance	15.93%	-0.17%	1.08%	3.81%
1 Year Performance	N/A	-38.62%	10.03%	23.90%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.1175 of 5 stars	$10.48 flat	$14.20 +35.5%	N/A	$875.45M	$576.30M	25.56	1,200	News Coverage Analyst Forecast
WRBY Warby Parker	2.7638 of 5 stars	$29.11 +5.9%	$29.50 +1.3%	+31.1%	$2.95B	$890.57M	1,456.23	4,036	News Coverage Insider Trade
TMDX TransMedics Group	4.3175 of 5 stars	$68.44 -12.0%	$134.50 +96.5%	-46.5%	$2.69B	$605.49M	15.55	210	Analyst Forecast High Trading Volume
ESTA Establishment Labs	1.4504 of 5 stars	$88.38 -0.8%	$87.14 -1.4%	+103.3%	$2.62B	$211.08M	N/A	1,004	High Trading Volume
AXGN AxoGen	2.0182 of 5 stars	$44.93 +1.0%	$46.50 +3.5%	+320.2%	$2.37B	$225.21M	N/A	450	News Coverage Positive News Analyst Upgrade Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors

BVS vs. WRBY, TMDX, ESTA, AXGN, and LMAT

How does Bioventus compare to Warby Parker?

Summary

How does Bioventus compare to TransMedics Group?

Summary

How does Bioventus compare to Establishment Labs?

Summary

How does Bioventus compare to AxoGen?

Summary

How does Bioventus compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Competitors

BVS vs. WRBY, TMDX, ESTA, AXGN, and LMAT

How does Bioventus compare to Warby Parker?

Which has preferable earnings & valuation, BVS or WRBY?

Do analysts recommend BVS or WRBY?

Which has more volatility & risk, BVS or WRBY?

Is BVS or WRBY more profitable?

Do insiders and institutionals have more ownership in BVS or WRBY?

Does the media refer more to BVS or WRBY?

Summary

How does Bioventus compare to TransMedics Group?

Is BVS or TMDX more profitable?

Which has preferable valuation and earnings, BVS or TMDX?

Does the media refer more to BVS or TMDX?

Which has more volatility & risk, BVS or TMDX?

Do analysts prefer BVS or TMDX?

Do insiders & institutionals believe in BVS or TMDX?

Summary

How does Bioventus compare to Establishment Labs?

Do analysts prefer ESTA or BVS?

Which has preferable earnings & valuation, ESTA or BVS?

Does the media favor ESTA or BVS?

Do insiders and institutionals believe in ESTA or BVS?

Which has more volatility and risk, ESTA or BVS?

Is ESTA or BVS more profitable?

Summary

How does Bioventus compare to AxoGen?

Do analysts rate AXGN or BVS?

Which has higher earnings & valuation, AXGN or BVS?

Is AXGN or BVS more profitable?

Which has more risk & volatility, AXGN or BVS?

Do insiders & institutionals hold more shares of AXGN or BVS?

Does the media refer more to AXGN or BVS?

Summary

How does Bioventus compare to LeMaitre Vascular?

Which has more risk and volatility, BVS or LMAT?

Is BVS or LMAT more profitable?

Which has better valuation & earnings, BVS or LMAT?

Do insiders and institutionals have more ownership in BVS or LMAT?

Does the media favor BVS or LMAT?

Do analysts rate BVS or LMAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools